Breaking News

Intellipharmaceutics Receives Sales Milestone from Par

By Kristin Brooks | February 3, 2014

$3.1 million payment represents its share of ADHD drug sales

Intellipharmaceutics International has received approximately $3.1 million under its licensing agreement with Par Pharmaceutical as its first payment relating to commercial sales of ADHD treatment dexmethylphenidate hydrochloride extended-release capsules. The payment represents its share of profits for the 15 and 30 mg strengths of the drug for the period beginning November 19, 2013 and ending December 31, 2013. Future profit-share payments are expected on a quarterly basis.
 
As the first-filer for the drug product in the 15 mg strength, Par currently has 180 days of exclusivity of generic sales from the November 19, 2013 date of launch in the U.S. In addition, Intellipharmaceutics has the potential to receive its share of the profits on the 5, 10, 20 and 40 mg strengths, which were also tentatively approved by FDA.

blog comments powered by Disqus
  • Single-Use Clarification System for High-Density Cell Cultures

    Single-Use Clarification System for High-Density Cell Cultures

    Tjebbe van der Meer, Sartorius Stedim Biotech||June 2, 2015
    Continuous improvements in growth media and cell line viability have resulted in increased biomass concentrations in biopharmaceutical production processes, making the downstream purification step more challenging. Body feed filtration has proven to be a successful method of solving similar issues in other industries. This robust technology is now available as a harvesting solution for biotechnology applications.

  • Newsmakers: John Chiminski

    Newsmakers: John Chiminski

    May 6, 2015
    Catalent Completes $52M Expansion at Winchester, KY, Facility

  • Will All Tablets and Capsules Have On-Dose Physical Chemical Identifiers Soon?

    Will All Tablets and Capsules Have On-Dose Physical Chemical Identifiers Soon?

    Kent Mansfield , president TruTag Technologies, Inc.||April 1, 2015
    As the global problem of counterfeit and diverted drugs continues to grow worldwide, will our medicine soon carry secure identifiers woven into the very fabric of the drug product? Advancing technology is finally allowing drug makers the ability to implement on-dose authentication.